← Back to Clinical Trials
Recruiting NCT07552701

NCT07552701 USG-Guided TAPA vs RIFB Block for Postoperative Analgesia in Laparoscopic Cholecystectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07552701
Status Recruiting
Phase
Sponsor Hitit University
Condition Postoperative Pain
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2025-03-16
Primary Completion 2026-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
M-TAPA GroupRIFPB Group

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2025-03-16 with a primary completion date of 2026-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Laparoscopic cholecystectomy (LC) can cause moderate-to-severe postoperative pain from visceral, referred shoulder, and incisional sources. Multimodal analgesia is recommended, but opioids carry significant side effects. Ultrasound-guided interfascial plane blocks offer a safe alternative. The Modified Thoracoabdominal Nerve Block through Perichondrial Approach (M-TAPA) blocks T5-T12 dermatomes, while the Recto-Intercostal Fascial Plane Block (RIFPB) provides sensory blockade across the upper anterolateral abdomen. This study compares the postoperative analgesic efficacy of bilateral M-TAPA versus bilateral RIFPB in patients undergoing LC.

Eligibility Criteria

Inclusion Criteria: * Age 18-65 years * ASA physical classification I-II * BMI \< 35 kg/m² * Scheduled for elective laparoscopic cholecystectomy due to cholelithiasis * Able to use and understand the NRS pain scoring system * Able to use and understand the QoR-15 scale * Able to communicate in Turkish * Provided written informed consent Exclusion Criteria: * Refusal to participate in the study * BMI \> 35 kg/m² * ASA physical classification III-V * Age \< 18 or \> 65 years * Allergy to local anesthetics or study analgesics * Pregnancy or breastfeeding * Inability to use or understand the NRS pain scoring system or QoR-15 scale * Inability to communicate in Turkish * Uncontrolled anxiety disorder * Alcohol or drug dependency * Neuromuscular or peripheral nerve disease * High-dose opioid use within 3 days prior to surgery * Widespread chronic pain * Diabetes mellitus * Hepatic or renal insufficiency * Coagulation disorders or anticoagulant use * Infection at the block needle insertion site * Concurrent second surgical procedure alongside laparoscopic cholecystectomy * Previous abdominal surgery or trauma history * Conversion from laparoscopic to open surgery * Technical problems with the PCA device * NRS score \> 7 for four consecutive hours despite multimodal analgesia * Planned postoperative non-extubation * Termination of surgery before completion for any reason

Contact & Investigator

Central Contact

Hakan Akel, MD

✉ drhakanakel@gmail.com

📞 +905442094827

Principal Investigator

Guvenc Dogan, MD

STUDY CHAIR

Hitit University

Frequently Asked Questions

Who can join the NCT07552701 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Postoperative Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07552701 currently recruiting?

Yes, NCT07552701 is actively recruiting participants. Contact the research team at drhakanakel@gmail.com for enrollment information.

Where is the NCT07552701 trial being conducted?

This trial is being conducted at Çorum, Turkey (Türkiye).

Who is sponsoring the NCT07552701 clinical trial?

NCT07552701 is sponsored by Hitit University. The principal investigator is Guvenc Dogan, MD at Hitit University. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology